FDA Approved: CRESTOR — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a Supplemental Application for CRESTOR (rosuvastatin) submitted by AstraZeneca Pharmaceuticals LP, updating the drug's labeling/indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipidemia

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

SUPPL AP for CRESTOR (ROSUVASTATIN)